The abstract is read at the publisher; the summary is JClub's.
Frontotemporal dementia patients show increased GrimAge2-derived epigenetic age acceleration (β = 1.17 ± 0.36, 95% CI 0.46–1.88, p = 0.001) versus controls in two blood cohorts.
- Why it matters: Epigenetic clocks track biological aging shaped by lifestyle and systemic signals, but whether this aging acceleration is relevant to frontotemporal dementia was unclear.
- What they did: Using peripheral blood DNA methylation from 313 patients/121 controls (Amsterdam Dementia Cohort) and 102 patients/102 controls (Genetic Investigation in Frontotemporal Dementia), the study tested diagnosis associations with linear regression and meta-analysis, then analyzed smoking-related methylation, inflammatory markers, and glycated hemoglobin.
- The result: Component analyses linked the signal to increased smoking-related DNA methylation, systemic inflammation (tissue inhibitor of metalloproteinases 1, C-reactive protein), and glucose metabolism (all p < 0.05); adjusting for smoking-related methylation attenuated the effect by ~48% (β = 0.62 ± 0.32, 95% CI -0.01–1.24, p = 0.053).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.